Correlation Between Abattis Bioceuticals and Mydecine Innovations

Can any of the company-specific risk be diversified away by investing in both Abattis Bioceuticals and Mydecine Innovations at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Abattis Bioceuticals and Mydecine Innovations into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Abattis Bioceuticals Corp and Mydecine Innovations Group, you can compare the effects of market volatilities on Abattis Bioceuticals and Mydecine Innovations and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Abattis Bioceuticals with a short position of Mydecine Innovations. Check out your portfolio center. Please also check ongoing floating volatility patterns of Abattis Bioceuticals and Mydecine Innovations.

Diversification Opportunities for Abattis Bioceuticals and Mydecine Innovations

0.0

Correlation Coefficient

Abattis Bioceuticals  Mydecine Innovations

Pay attention - limited upside

The 3 months correlation between Abattis and Mydecine is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Abattis Bioceuticals Corp and Mydecine Innovations Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mydecine Innovations and Abattis Bioceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Abattis Bioceuticals Corp are associated (or correlated) with Mydecine Innovations. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mydecine Innovations has no effect on the direction of Abattis Bioceuticals i.e., Abattis Bioceuticals and Mydecine Innovations go up and down completely randomly.

Pair Corralation between Abattis Bioceuticals and Mydecine Innovations

If you would invest  5.20  in Mydecine Innovations Group on October 8, 2024 and sell it today you would lose (4.80) from holding Mydecine Innovations Group or give up 92.31% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Abattis Bioceuticals Corp  vs.  Mydecine Innovations Group

Abattis Bioceuticals Corp

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Abattis Bioceuticals Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental drivers, Abattis Bioceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders.

Mydecine Innovations

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Mydecine Innovations Group are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain basic indicators, Mydecine Innovations reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Abattis Bioceuticals and Mydecine Innovations

The main advantage of trading using opposite Abattis Bioceuticals and Mydecine Innovations positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Abattis Bioceuticals position performs unexpectedly, Mydecine Innovations can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mydecine Innovations will offset losses from the drop in Mydecine Innovations' long position.

The idea behind Abattis Bioceuticals Corp and Mydecine Innovations Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.